JGC
SPPI

J. Goldman & Co’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

J. Goldman & Co’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-32,500
Closed -$546K – 337
2018
Q3 		$546K Buy
+32,500
New +$703K 0.04% 219

Other funds holding SPPI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

J. Goldman & Co's SPPI Position: Q1 2019 in Review

J. Goldman & Co sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q1 2019, closing a stake of 267,801 shares — an estimated $2.34M sold.

J. Goldman & Co first reported a position in SPPI in Q1 2015 and held it in 7 quarters. The position peaked at $14.6M in Q2 2018. 173 funds tracked by Wall St. Rank hold SPPI as of Q1 2019.

  • J. Goldman & Co reported no remaining Spectrum Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • J. Goldman & Co sold 267,801 Spectrum Pharmaceuticals Inc shares in Q1 2019, an estimated $2.34M.
  • J. Goldman & Co first reported a position in Spectrum Pharmaceuticals Inc in Q1 2015 and held it in 7 quarters.
  • J. Goldman & Co's Spectrum Pharmaceuticals Inc position peaked at $14.6M in Q2 2018.
  • 173 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q1 2019.

Based on J. Goldman & Co's 13F filing for Q1 2019, filed 14 May 2019.